%0 Journal Article %A Dennis Kraemer %A Dillenn Terumalai %A Maria Livia Famiglietti %A Isabel Filges %A Pascal Joset %A Samuel Koller %A Fabienne Maurer %A Stéphanie Meier %A Thierry Nouspikel %A Javier Sanz %A Christiane Zweier %A Marc Abramowicz %A Wolfgang Berger %A Sven Cichon %A André Schaller %A Andrea Superti-Furga %A Valérie Barbié %A Anita Rauch %T SwissGenVar: A platform for clinical grade interpretation of genetic variants to foster personalized health care in Switzerland %D 2023 %R 10.1101/2023.01.11.22283790 %J medRxiv %P 2023.01.11.22283790 %X Large-scale next-generation sequencing (NGS) germline testing is technically feasible today, but variant interpretation represents a major bottleneck in analysis workflows including the extensive variant prioritization, annotation, and time-consuming evidence curation. The scale of the interpretation problem is massive, and variants of uncertain significance (VUS) are a challenge to personalized medicine. This challenge is further compounded by the complexity and heterogeneity of standards used to describe genetic variants and associated phenotypes when searching for relevant information to inform clinical decision-making.For this purpose, all five Swiss academic Medical Genetics Institutions joined forces with the Swiss Institute of Bioinformatics (SIB) to create SwissGenVar as a user-friendly nationwide repository and sharing platform for genetic variant data generated during routine diagnostic procedures and research sequencing projects. Its objective is to provide a protected environment for expert evidence sharing about individual variants to harmonize and up-scale their significance interpretation at clinical grade following international standards. To corroborate the clinical assessment, the variant-related data are combined with consented high-quality clinical information. Broader visibility will be gained by interfacing with international databases, thus supporting global initiatives in personalized health care.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis platform development was funded as infrastructure development project (2018DEV13) by the Swiss Personalized Health Network (SPHN).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe SwissGenVar documentation and public website are available at https://pages.sib.swiss/project/swissgenvar-doc/ and https://pages.sib.swiss/project/swissgenvar/, respectively. The project GitLab site is available at URL https://gitlab.sib.swiss/clinbio/swissgenvar/sgv-knowledge/-/tree/master. %U https://www.medrxiv.org/content/medrxiv/early/2023/01/11/2023.01.11.22283790.full.pdf